Investigating how mitochondrial dysfunction affects tau pathology in Alzheimer's disease

Mitochondrial dysfunction and tau pathology in Alzheimer's disease

NIH-funded research University of Rochester · NIH-10805120

This study is looking at how problems with tiny energy factories in our cells, called mitochondria, might be linked to the brain changes seen in Alzheimer's disease, and it uses special light technology to see how these issues affect brain health in both lab samples and live mice.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionUniversity of Rochester NIH-funded
Lab location1 site (Rochester, United States)
Project IDNIH-10805120 on NIH RePORTER

What this research studies

This research explores the relationship between mitochondrial dysfunction and tau pathology in Alzheimer's disease (AD), which is a leading cause of dementia. Using innovative optogenetic technology, the study aims to manipulate mitochondrial function and reactive oxygen species (ROS) production in real-time to determine their roles in the progression of tau pathology. By employing light-activated tools, researchers will be able to control these processes in both brain slice cultures and live mouse models, providing insights into the underlying mechanisms of AD. This approach seeks to clarify the complex interactions between these factors and their impact on neuronal health.

Who could benefit from this research

Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing symptoms of Alzheimer's disease or are at risk for developing it.

Not a fit: Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies that slow or halt the progression of Alzheimer's disease.

How similar studies have performed: While the specific optogenetic approach is novel, previous research has shown that targeting mitochondrial function can have beneficial effects in neurodegenerative diseases.

Where this research is happening

Rochester, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndrome
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.